Aesynt Launches REINVENT Registry to Enable Insight and Innovation in IV Pharmacy Automation

First-of-its-kind registry to provide healthcare organizations with powerful IV automation analytics through aggregated compounded sterile preparation data

CRANBERRY TOWNSHIP, Pa.--()--AesyntTM, a leading provider of integrated pharmacy automation solutions for hospitals and health systems, today announced the launch of the Registry for Intravenous Technology in Pharmacy (REINVENT™), a global, multi-site data registry aimed at collecting compounded sterile preparation (CSP) data from hospitals and health systems for evaluation, analysis and insight. The registry is the first of its kind within the IV automation space, providing the industry and healthcare organizations with a powerful analytics tool that leverages large datasets to enhance the value of automation technology and improve patient care.

By leveraging the aggregated data collected from Aesynt’s i.v.STATION™, registry participants can analyze current industry trends, benchmark measures for process improvement and continue to innovate within the IV compounding space. This capability will help these organizations improve operational efficiencies and safety for both employees and patients, while also supporting cost reductions.

“As more hospitals and health systems are now looking to insource and automate their IV compounding processes, REINVENT can help these organizations see the benefit of IV automation and help them adopt and utilize the technology for the benefit of patients,” said John Barickman, Senior Executive Pharmacy Consultant of IV Automation at Aesynt.

REINVENT data, which is stripped of site identification and is HIPAA-compliant, will be available to Aesynt’s i.v.STATION customers who have opted-in to the registry. The first subset of data will be available this year. The registry will:

  • Automatically gather data from participating i.v.STATION customers through a remote connection;
  • Aggregate and analyze that data to study metrics, such as dose accuracy, site productivity and drug yield, including descriptive statistics and performance assessment over set periods of time;
  • Showcase both high level industry trends and site, drug or final container-specific data, benchmarking customers against comparable sites; and
  • Help customers adopt and best utilize state-of-the-art automation technology through continued innovation.

“REINVENT changes how hospitals and health systems think about IV pharmacy, driving innovation for improved outcomes for both patients and healthcare organizations”, said Doug Descalzi, Senior Vice President and General Manager of IV Solutions at Aesynt. “As the only company in the market offering a full line of pharmacy automation solutions, Aesynt is committed to enabling pharmacies to evolve and prosper in a challenging time for healthcare through novel tools and techniques, such as big data and registries, which will allow us to achieve and share our vision with our customers.”

To register to participate in the REINVENT registry, or to learn more, please call (724) 741-6780 or visit http://www.aesynt.com/iv-solutions/reinvent.

About Aesynt

Aesynt Incorporated is committed to continuously advancing medication management, offering integrated pharmacy automation solutions that help health systems to support improved patient outcomes, build stronger businesses and manage ongoing change. For more information, visit www.aesynt.com. Follow Aesynt on Twitter at https://twitter.com/aesynt.

Contacts

Dodge Communications
Kelcie Chambers, 770-992-2471
kchambers@dodgecommunications.com

Contacts

Dodge Communications
Kelcie Chambers, 770-992-2471
kchambers@dodgecommunications.com